NCT00493467 - Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2015

Study Completion Date

August 11, 2022

Conditions

Lymphoma

Interventions

DRUG

Ibritumomab Tiuxetan (Zevalin)

"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."

DRUG

Rituximab

250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston